OverviewSuggest Edit
Transgene (Euronext: TNG),
part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
| Type | Public | |
| HQ | Illkirch, FR | Map |
| Website | transgene.fr |
Recent NewsAll News
- BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors
- CTIBiotech - Transgene Collaboration for Cancer Research
- AstraZeneca ties up with France's Transgene to develop viral immunotherapies
- BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Key People/Management at Transgene
Juan Pedro R. Serrate
Analyst
Transgene Office Locations
Transgene has offices in Illkirch, Lyon, Boston and Shanghai
Shanghai, CN
Rm 508, Building 2 4633, Pusan Road Kangqiao Industrial Park, Pudong Shanghai
Lyon, FR
321 Avenue Jean Jaurès
Boston, US
201 Washington St
Transgene Financials and Metrics
Transgene Revenue
Market capitalization (28-Sept-2020) | 102.8m |
Closing stock price (28-Sept-2020) | 1.2 |
Transgene's current market capitalization is €102.8 m.
Transgene Cybersecurity Score
Transgene Online and Social Media Presence
1.32k Twitter followers
Transgene has 1.32k Twitter Followers. The number of followers has increased 0.9% month over month and increased 4% quarter over quarter
Transgene's Trends
Twitter Engagement Stats for @TransgeneSA
1.1k
Tweets
451
Following
1.3k
Followers
6
Tweets last 30 days
0.2
Avg. likes per Tweet
50%
Tweets with engagement
Transgene News and Updates
December 11, 2019
BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors
LUND, Sweden and STRASBOURG, France, Dec. 11, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris:...
November 06, 2019
CTIBiotech - Transgene Collaboration for Cancer Research
CTIBioTumour: Human Tumours Produced by 3D Bioprinting to Accelerate the Development of New Cancer Therapies
May 02, 2019
AstraZeneca ties up with France's Transgene to develop viral immunotherapies
British drugmaker AstraZeneca Plc
and French biopharmaceutical firm Transgene SA entered
into an agreement on Thursday to co-develop five cancer-killing
viral immunotherapies.
March 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
LUND, Sweden and STRASBOURG, France, March 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer and Transgene (Euronext Paris: TNG), a biotech company that designs ...
February 15, 2019
Transgene Biotek reports standalone net loss of Rs 0.93 crore in the December 2018 quarter
Reported sales nil
November 22, 2018
Gene Therapy Market to Set Phenomenal Growth from 2018 to 2026 Estimated by Global Top Players GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA
#Summary: Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twi…
Transgene Blogs
November 06, 2019
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 Download the poster here Poster Presentation
September 30, 2019
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Transgene Frequently Asked Questions
Who are Transgene key executives?
Transgene's key executives are Juan Pedro R. Serrate.
How many employees does Transgene have?
Transgene has 136 employees.
Who are Transgene competitors?
Competitors of Transgene include Magenta Therapeutics, Synthace and ProtoKinetix.
Where are Transgene offices?
Transgene has offices in Illkirch, Lyon, Boston and Shanghai.
How many offices does Transgene have?
Transgene has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies